Rupali Jain

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

José M. Munita, Samuel L Aitken, William R. Miller et al. · Clinical Infectious Diseases · 2017 · 134 citations · Full text

Multicenter Evaluation, Antimicrobial Chemotherapy, Drug Resistance +16

Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen

Brian J. Werth, Rupali Jain, Andrew W. Hahn et al. · Clinical Microbiology and Infection · 2017 · 96 citations · Full text

Vancomycin-containing Regimen, Antibiotics, Health Sciences +8

Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events

Helen Y. Chu, Rupali Jain, Hu Xie et al. · BMC Infectious Diseases · 2013 · 73 citations · Full text

Aerosolized ribavirin: the most expensive drug for pneumonia

Roy F. Chemaly, Samuel L Aitken, Cameron R. Wolfe et al. · Transplant Infectious Disease · 2016 · 58 citations

Transplant Procedure, Transplantation, Health Economics +12

Impact of rapid influenza PCR testing on hospitalization and antiviral use: A retrospective cohort study

Helen Y. Chu, Janet A. Englund, Dandi Huang et al. · Journal of Medical Virology · 2015 · 51 citations · Full text

Vaccination, Antiviral Use, Retrospective Cohort Study +13